Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Frequently asked questions
What sector does Akero Therapeutics, Inc (AKRO) operate in?
Akero Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Akero Therapeutics, Inc (AKRO) current stock price?
As of the latest data, Akero Therapeutics, Inc stock price is $54.65, with a previous close of $54.65.
What is Akero Therapeutics, Inc (AKRO) current market capitalization?
Akero Therapeutics, Inc market cap is approximately 4.50 billion.
What is Akero Therapeutics, Inc (AKRO) Earnings Per Share (EPS)?
The trailing EPS is -$3.75, and the forward EPS is -$4.22.
Does Akero Therapeutics, Inc (AKRO) pay dividends?
No. Akero Therapeutics, Inc does not pay a dividend.
What is Akero Therapeutics, Inc (AKRO) beta (volatility) score?
Akero Therapeutics, Inc has a beta of -0.404, indicating lower volatility than the overall market.
